TABLE 4.
Clinical outcomesa
| Ceftazidime-avibactam group (n = 105) | Meropenem-vaborbactam group (n = 26) | P value | |
|---|---|---|---|
| No. of clinical successesb (%) | 65 (61.9) | 18 (69.2) | 0.49 |
| No. of failures to resolve signs and symptoms of infection (%) | 4 (3.8) | 1 (3.8) | 1.0 |
| Failure to sterilize blood cultures within 7 days of treatment initiation [no. of failures/no. of bacteremias (%)] | 1/44 (2.3) | 1/9 (11.1) | 0.31 |
| No. of 30-day mortalities (%) | 20 (19.1) | 3 (11.5) | 0.57 |
| No. of 90-day mortalities (%) | 30 (28.6) | 7 (26.9) | 0.48 |
| Median length of hospital stayc (days) (IQR) | 15.3 (9.3–28.5) | 15.6 (9.5–33.1) | 0.99 |
| Median length of ICU stay (days) (IQR) | 15.0 (5.0–32.0) | 12.0 (5.0–22.0) | 0.53 |
| No. of recurrences of CRE infection (%) | 15 (14.3) | 3 (11.5) | 1.0 |
| No. of increases in study drug MIC in mg/liter (%) | 6 (40.0) | 0 | 0.51 |
| No. of emergences of study drug resistance (%) | 3 (20.0) | 0 | 1.0 |
a
CRE, carbapenem-resistant Enterobacteriaceae; ICU, intensive care unit; IQR, interquartile range.
b
Clinical success was defined as survival at 30 days, resolution of signs and symptoms of infection, sterilization of blood cultures within 7 days of treatment initiation in patients with bacteremia, and absence of recurrent infections within 90 days of the index infection.
c
Length of stay was calculated from onset of CRE infection.